KALARIS THERAPEUTICS INC (KLRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.90-1.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KLRS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 32.9 | 30.8 | 12.3 | 133.1 | 118.9 | 120.7 | 49.7 |
| Operating Income | (47.8) | (46.2) | (65.4) | (199.9) | (171.2) | (169.8) | (71.3) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | 1.4 | — | — | — | — | — |
| Interest & Investment Income | — | — | 5.5 | 5.7 | 1.9 | 1.3 | 1.3 |
| Other Non-Operating Income / Expenses | 3.5 | 2.7 | — | — | — | — | — |
| Asset Writedown | — | — | — | 18.6 | — | — | — |
| EBT, Incl. Unusual Items | — | (43.4) | (58.8) | (190.5) | (169.0) | (171.0) | (69.8) |
| Income Tax Expense | — | — | — | (0.1) | (0.3) | 1.0 | — |
| Net Income | |||||||
| Net Income | (44.3) | (43.4) | (58.8) | (190.4) | (168.7) | (172.0) | (69.8) |
| Per Share | |||||||
| Basic EPS | (1.86) | (2.85) | (11.73) | (42.09) | (2.20) | (2.74) | — |
| Diluted EPS | (1.86) | (2.85) | (11.73) | (42.09) | (2.20) | (2.74) | — |
| Basic Weighted Avg Shares | 23.8 | 15.3 | 5.0 | 4.5 | 76.7 | 62.8 | — |
| Diluted Weighted Avg Shares | 23.8 | 15.3 | 5.0 | 4.5 | 76.7 | 62.8 | — |
| Supplemental | |||||||
| EBITDA | — | — | — | (199.5) | (170.5) | (169.6) | (71.2) |
| EBIT | (47.8) | (46.2) | (65.4) | (199.9) | (171.2) | (169.8) | (71.3) |
| Effective Tax Rate | — | — | — | 0.1% | 0.2% | -0.6% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.